<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364287">
  <stage>Registered</stage>
  <submitdate>21/05/2013</submitdate>
  <approvaldate>24/05/2013</approvaldate>
  <actrnumber>ACTRN12613000586718</actrnumber>
  <trial_identification>
    <studytitle>Updating the efficacy study of artemether-lumefantrine for the treatment of uncomplicated P falciparum malaria in sentinel sites in the Comoros Islands.</studytitle>
    <scientifictitle>Safety and efficacy, in terms of adequate clinical and parasitological response,  of artemether lumefantrine for the treatment of children with uncomplicated P. falciparum malaria in Comoros Islands. </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>uncomplicated falciparum malaria</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Therapeutic efficacy study of the fixed combination of artemether-lumefantrine ( 20 mg artemether/ 120 mg lumefantrine) administered orally twice a day for three consecutive days. The number of tablets to be administered at each dosing day will be based on body weight as per standard of care.  Patients will be seen daily for the first three days and then return to the health center weekly (day 7, 14, 21 and 28)  for clinical and parasitological evaluation or any other day if symptoms re-occurred.   </interventions>
    <comparator>No control
</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of patients with adequate clinical and parasitological response adjusted by PCR (polymerase chain reaction)</outcome>
      <timepoint>Day 28</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nature and incidence of adverse events as observed by investigators or reported by patients. Clinical laboratory testing may be performed to confirm a diagnosis. Possible adverse events include those know to occur with  such antimalarial and include, headache, nausea, abdominal discofort, dizziness.</outcome>
      <timepoint>Day 28</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Age between 6 months to 11 years (inclusive);
Monoinfection with P falciparum, microscopically confirmed
Parasitaemia between 500-200,000 per microliter (asexual forms)
Axillary temperature equal or greater than 37.5 degrees C;
Able to swallow oral medication;
Capable and willing to fulfill protocol requirements, including the schedule of assessments for the duration of the study;
Provide written informed consent (parent or guardian) </inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>11</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Presence of general danger and signs in children under 5 years or signs of severe falciparum malaria;
Mixed or mono-infection with another Plasmodium species detected by microscopy;
History of hypersensitivity reactions or contraindications to any of the medicines being tested or used as alternative treatments(s); 
Severe malnutrition (per WHO definition);
Presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea);
Regular medication, which may interfere with antimalarial pharmacokinetics</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/06/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>560</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Comoros</country>
      <state>Ngazidja</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Comoros</country>
      <state>Mwali</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Comoros</country>
      <state>Ndzouani</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Ministere de la Sante, de la Solidarite et de la Promotion du Genre</primarysponsorname>
    <primarysponsoraddress>Centre National de Lutte contre le Paludisme/
C/O Organisation Mondiale de la Sante
Itsambouni
B.P. 435
Moroni, Grande Comore 
</primarysponsoraddress>
    <primarysponsorcountry>Comoros</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Ministere de la Sante, de la Solidarite et de la Promotion du Genre
</fundingname>
      <fundingaddress>Centre National de Lutte contre le Paludisme/
C/O Organisation Mondiale de la Sante
Itsambouni
B.P. 435
Moroni, Grande Comore</fundingaddress>
      <fundingcountry>Comoros</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>World Health Organisation</fundingname>
      <fundingaddress>20 Avenue Appia
1211 Geneva</fundingaddress>
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>Institut Pasteur de Madagascar
</othercollaboratorname>
      <othercollaboratoraddress>B.P. 1274
Ambatofotsikely
101 Antananarivo
</othercollaboratoraddress>
      <othercollaboratorcountry>Madagascar</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Therapeutic efficacy study of the fixed combination of artemether-lumefantrine (20 mg artemether/ 120 mg lumefantrine) administered orally twice a day for three consecutive days. The number of tablets per dosing will be based on body weight per standard of care. Patients will be seen daily for the first three days and then return to the health center weekly (day 7, 14, 21 and 28) for clinical and parasitological evaluation or any other day if symptoms re-occurred. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>WHO ERC</ethicname>
      <ethicaddress>World Health Organisation
20 Avenue Appia
1211 Geneva</ethicaddress>
      <ethicapprovaldate>14/05/2013</ethicapprovaldate>
      <hrec>RPC570</hrec>
      <ethicsubmitdate>20/03/2013</ethicsubmitdate>
      <ethiccountry>Switzerland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Mrs</title>
      <name>Rahamatou SILAI</name>
      <address>Ministere de la Sante, de la Solidarite et de la Promotion du Genre a l'Union des Comores
C/O Organisation Mondiale de la Sante
Itsambouni 
B.P. 435
Moroni
Grande Comore</address>
      <phone>+2693330375</phone>
      <fax />
      <email>rsilai.pnlp@laposte.net</email>
      <country>Comoros</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Rahamatou SILAI</name>
      <address>Ministere de la Sante, de la Solidarite et de la Promotion du Genre a l'Union des Comores
C/O Organisation Mondiale de la Sante
Itsambouni 
B.P. 435
Moroni
Grande Comore</address>
      <phone>+2693330375</phone>
      <fax />
      <email>rsilai.pnlp@laposte.net</email>
      <country>Comoros</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Rahamatou SILAI</name>
      <address>Ministere de la Sante, de la Solidarite et de la Promotion du Genre a l'Union des Comores
C/O Organisation Mondiale de la Sante
Itsambouni 
B.P. 435
Moroni
Grande Comore</address>
      <phone>+2693330375</phone>
      <fax />
      <email>rsilai.pnlp@laposte.net</email>
      <country>Comoros</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Pascal Ringwald</name>
      <address>World Health Organisation
20 Avenue Appia 
1211 Geneva
</address>
      <phone>+41227913469</phone>
      <fax />
      <email>ringwaldp@who.int</email>
      <country>Switzerland</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>